Komori
Ono Pharmaceutical (4528) · PolicyAdvanced

Holding Shares to Maintain and Strengthen Business Relationships

First written in FY2016. 8 of 12 entries say "Advanced", first in FY2020. Latest entry: FY2026.

12entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018AdvancedFY2020 – FY20262016: 120162017: 120172018: 120182019: 120192020: 120202021: 120212022: 120222023: 120232024: 120242025: 120252026: 22026
Same theme, other companies
Verifying the Rationale for Holding Cross-ShareholdingsA theme 1258 companies write about · 1 as a headwind · 666 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1262 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「As a result, the Company decided to proceed with reducing certain holdings that it determined had become less rational to retain, while seeking the investee companies' understanding through dialogue. The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows. / Shares other than unlisted shares: 7 holdings, ¥12,968 million」

    Regarding strategic shareholdings, the Company continued reducing holdings based on its review of their rationality, selling 7 listed and other holdings for ¥12,968 million during the fiscal year.
  2. 2026-05-21AdvancedGeneral Meetings of Shareholders

    「We will continue working to reduce these holdings to enhance our corporate value.」

    Cross-shareholdings were reduced from 67 to 48 issues, and the ratio to consolidated net assets declined from 17.2% to 9.0%, with the reduction policy continuing.
  3. FY2025AdvancedAnnual report

    「The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows. / Unlisted shares: – / Shares other than unlisted shares: 9 holdings, ¥18,697 million」

    The Company continued reducing strategic shareholdings based on its review of their rationality, selling 9 listed and other holdings for ¥18,697 million during the fiscal year.
  4. FY2024AdvancedAnnual report

    「The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows. / Unlisted shares: – / Shares other than unlisted shares: 7 holdings, ¥17,667 million」

    The Company continued reducing strategic shareholdings based on its review of their rationality, selling 7 listed and other holdings for ¥17,667 million and 1 unlisted holding for ¥2 million during the fiscal year.
  5. FY2023AdvancedAnnual report

    「As a result, the Company decided to proceed with reducing certain holdings that it determined had become less rational to retain, while seeking the investee companies' understanding through dialogue. The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares were as follows: 7 holdings other than unlisted shares, ¥7,804 million.」

    The Company continued reducing strategic shareholdings based on its review of their rationality, selling 7 listed and other holdings for ¥7,804 million during the fiscal year.
  6. FY2022AdvancedAnnual report

    「As a result, the Company decided to proceed with reducing certain holdings that it determined had become less rational to retain, while seeking the investee companies' understanding through dialogue. The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows. / Unlisted shares: 4 holdings, ¥272 million / Shares other than unlisted shares: 10 holdings, ¥18,398 million」

    The Company continued reducing strategic shareholdings based on its review of their rationality, selling 10 listed and other holdings for ¥18,398 million and 4 unlisted holdings for ¥272 million during the fiscal year.
  7. FY2021AdvancedAnnual report

    「As a result, the Company decided to proceed with reducing certain holdings that it determined had become less rational to retain, while seeking the investee companies' understanding through dialogue. The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows. / Shares other than unlisted shares: 17 holdings, ¥13,258 million」

    The Company continued reducing strategic shareholdings based on its review of their rationality, selling 17 holdings other than unlisted shares during the fiscal year for total proceeds of ¥13,258 million.
  8. FY2020AdvancedAnnual report

    「As a result, the Company decided to proceed with reducing certain holdings that it determined had become less rational to retain, while seeking the investee companies' understanding through dialogue. The number of holdings reduced during the fiscal year and the total sale proceeds from the reduction in the number of shares are as follows.」

    Regarding strategic shareholdings, the Company sold 9 holdings other than unlisted shares during the fiscal year, for total sale proceeds of ¥16,778 million.
  9. FY2019ReframedAnnual report

    「Going forward, where the Company determines from a medium- to long-term perspective that a holding will not contribute to enhancing corporate value, it will proceed with reducing the holding while seeking the investee company's understanding through dialogue. The Board of Directors will review each holding annually, examining its purpose, the benefits and risks associated with holding it, and other factors, and will make a determination after comprehensively considering the business relationship with the company and the creation of synergies.」

    The policy of holding shares to strengthen business relationships now explicitly incorporates an annual review of individual holdings and reductions in holdings that do not contribute to enhancing corporate value. The Company also states that it reduced 2 unlisted holdings and 24 listed holdings.
  10. FY2018RestatedAnnual report

    「Because the shares are held primarily to strengthen business relationships and enhance corporate value over the medium to long term, the Company has designated them as financial assets measured at fair value through other comprehensive income.」

    The Company reaffirmed its policy of holding strategic shareholdings to maintain and strengthen business relationships and enhance corporate value over the medium to long term.
  11. FY2017RestatedAnnual report

    「Because the shares are held primarily to strengthen business relationships and enhance corporate value over the medium to long term, the Company has designated them as financial assets measured at fair value through other comprehensive income.」

    The Company reaffirmed its policy of holding strategic shareholdings to maintain and strengthen business relationships and enhance corporate value over the medium to long term.
  12. FY2016First statedAnnual report

    「Because the shares are held primarily to strengthen business relationships and enhance corporate value over the medium to long term, the Company has designated them as financial assets measured at fair value through other comprehensive income.」

    The Company explains that its strategic shareholdings are held to strengthen business relationships with business partners and alliance partners and to enhance corporate value over the medium to long term.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 8 of its 12 moves.

887776★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs8×
  3. 2Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures8×
  4. 3In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials7×
  5. 4Global business expansion and international launches7×
  6. 5Expansion of Opdivo’s indications and progress in international development and sales7×
  7. 6Strengthening the R&D organization by incorporating the world's most advanced expertise and technologies6×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-05-21: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Holding Shares to Maintain and Strengthen Business Relationships | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori